You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MYC Overexpression

Showing 1 - 25 of 300
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Poland, United

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +6 more
  • Cincinnati, Ohio
  • +4 more
Aug 3, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • San Antonio, Texas
    Next Oncology
Aug 9, 2022

Tumors Trial in Chile, United States (VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda)

Recruiting
  • Neoplasms
  • VIP152 (BAY 1251152)
  • +3 more
  • Springdale, Arkansas
  • +12 more
Mar 24, 2022

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Recruiting
  • NSCLC
  • +6 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Dec 20, 2022

Solid Tumor, Adult, Lymphoma Trial in Korea, Republic of, Spain, United States (Fadraciclib)

Recruiting
  • Solid Tumor, Adult
  • Lymphoma
  • Duarte, California
  • +3 more
Apr 1, 2022

CNS Tumor, Solid Tumor Trial in Worldwide (Nivolumab and Entinostat)

Recruiting
  • CNS Tumor
  • Solid Tumor
  • Nivolumab and Entinostat
  • Randwick, New South Wales, Australia
  • +13 more
Nov 8, 2022

Gastric Cancer Trial (Disitamab Vedotin Combined With Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin Combined With Sintilimab
  • (no location specified)
Jan 31, 2023

Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate

Not yet recruiting
  • Cancer of Cervix
  • Apoptosis
  • Immunohistochemistry
  • (no location specified)
Nov 17, 2023

HER2-overexpressed Advanced Solid Tumors After Progression of

Not yet recruiting
  • HER2
  • +3 more
  • Disitamab Vedotin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 14, 2022

STARD3 in Colorectal Cancer: The STAR Study

Recruiting
  • Colorectal Cancer
    • Aviano, Pordenone, Italy
      Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
    Nov 16, 2023

    DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

    Not yet recruiting
    • DLBCL
    • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
    • Qingdao, Shandong, China
      the affiliated hospital of Qingdao University
    Aug 18, 2022

    Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

    Not yet recruiting
    • Gastric Cancer
    • Disitamab Vedotin
    • +3 more
    • (no location specified)
    Nov 17, 2022

    Urothelial Carcinoma Trial in Beijing (18F-FDG)

    Recruiting
    • Urothelial Carcinoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jul 18, 2022

    Solid Tumor Trial (18F-FDG)

    Not yet recruiting
    • Solid Tumor
    • (no location specified)
    Jul 18, 2022

    Pancreatic Neuroendocrine Tumor Trial in Shanghai (Nimotuzumab)

    Not yet recruiting
    • Pancreatic Neuroendocrine Neoplasm
    • Shanghai, Shanghai, China
      Department of Pancreatic Surgery, Fudan University Shanghai Canc
    Apr 4, 2022

    Colorectal Cancer Trial (Anti-HER2 ADC)

    Not yet recruiting
    • Colorectal Cancer
    • Anti-HER2 ADC
    • (no location specified)
    Oct 12, 2022

    C-myc Biomarker Study for Diabetic Foot Ulcers

    Recruiting
    • Diabetes
    • +3 more
      • San Francisco, California
      • +5 more
      Mar 9, 2022

      Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in Beijing (RC48-ADC)

      Completed
      • Gastric Cancer
      • HER2 Overexpressing Gastric Carcinoma
      • Beijing, Beijing, China
        Beijing Cancer Hospital
      Jan 12, 2022

      Non Small Cell Lung Cancer Trial in Shanghai (RC48)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Jan 26, 2022

      Specific Protein Overexpression in Adult Non-Small Cell Lung

      Not yet recruiting
      • Non Small Cell Lung Cancer
        • (no location specified)
        Sep 29, 2023

        Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent Trial in Hanoi, Ho Chi Minh City (Faceptor, Herceptin,

        Completed
        • Breast Cancer Metastatic
        • +2 more
        • Hanoi, Vietnam
        • +1 more
        Mar 19, 2022

        Prostate Cancer Trial in United States (Docetaxel-PNP, Ribociclib, Prednisone)

        Completed
        Has Results
        • Prostate Cancer
        • San Francisco, California
        • +5 more
        Aug 9, 2022

        Klotho _ LRP-6 _ Gastric Adenocarcinoma

        Not yet recruiting
        • Gastric Adenocarcinoma
        • +2 more
        • Prognostic study
        • (no location specified)
        Jan 29, 2023

        Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

        Recruiting
        • Diffuse Large B-cell Lymphoma(DLBCL)
        • Zanubrutinib + R-CHOP
        • Shanghai, China
          Fudan University Shanghai Cancer Center
        Feb 10, 2022